US OptionsDetailed Quotes
MREO250516P3000
- 1.38
- 0.000.00%
15min DelayClose Apr 30 16:00 ET
0.00High0.00Low
1.38Open1.38Pre Close0 Volume475 Open Interest3.00Strike Price0.00Turnover527.02%IV37.45%PremiumMay 16, 2025Expiry Date0.41Intrinsic Value100Multiplier16DDays to Expiry0.97Extrinsic Value100Contract SizeAmericanOptions Type-0.3376Delta0.1281Gamma1.88Leverage Ratio-0.0331Theta-0.0009Rho-0.63Eff Leverage0.0020Vega
Mereo BioPharma Stock Discussion
Mereo BioPharma Secures 3-Year Cash Runway While Pushing Phase 3 Studies Forward
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
No comment yet